<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00107900</url>
  </required_header>
  <id_info>
    <org_study_id>DU176b-PRT007</org_study_id>
    <nct_id>NCT00107900</nct_id>
  </id_info>
  <brief_title>Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement</brief_title>
  <official_title>A Phase IIa, Multi-center, Multi-national, Open Label, Dose Ranging Study of the Efficacy, Safety, and Tolerability of Oral DU-176b Administered Once or Twice Daily in the Treatment of Adult Patients Undergoing Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      Patients who undergo total hip replacement surgery are at greater risk of getting deep vein
      thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of
      the study drug, DU-176b, in reducing the occurrence of deep vein thrombosis in patients
      having total hip replacement surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary study objective is to demonstrate prevention of venous thromboembolism in
      patients undergoing total hip replacement surgery. The secondary objective is to assess the
      safety and tolerability of DU-176.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevention of Venous Thromboembolism (VTE)</measure>
    <time_frame>2 weeks</time_frame>
    <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment (approximately 2 weeks post surgery).
Confirmed deep vein thrombosis ( both proximal and distal ) as assessed by unilateral or bilateral ascending contrast venograms 7 to 10 days following surgery Symptomatic and objectively proven Pulmonary Embolism (PE) prior to venography Symptomatic and objectively proven Deep Vein Thrombosis (DVT) prior to venography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Prothrombin Time (PT) Results</measure>
    <time_frame>end of treatment</time_frame>
    <description>Intent to Treat (ITT) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for International Normalized Ratio (INR) Results</measure>
    <time_frame>end of treatment</time_frame>
    <description>Intent to Treat (ITT) population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) Results</measure>
    <time_frame>end of treatment</time_frame>
    <description>Intent to Treat (ITT) population</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">606</enrollment>
  <condition>Arthroplasty, Replacement, Hip</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>15mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15mg edoxaban administered twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg edoxaban administered once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30mg edoxaban administered twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg edoxaban administered once daily (QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>60mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60mg edoxaban administered twice daily (BID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120mg QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg edoxaban administered once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DU-176b</intervention_name>
    <arm_group_label>15mg BID</arm_group_label>
    <arm_group_label>30mg QD</arm_group_label>
    <arm_group_label>30mg BID</arm_group_label>
    <arm_group_label>60mg QD</arm_group_label>
    <arm_group_label>60mg BID</arm_group_label>
    <arm_group_label>120mg QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unilateral hip replacement

        Exclusion Criteria:

          -  Patients scheduled for bilateral hip replacement in same procedure

          -  Patients with increased risk of bleeding

          -  Uncontrolled hypertension (BP greater than 180/100 mmHg)

          -  Patients less than 111 lbs or more than 243 lbs

          -  Patients on long-term anticoagulants

          -  Patients with contraindications to venography

          -  Patients with medical history of venous thromboembolism

          -  Patients with impaired hepatic function

          -  Known to be pregnant

          -  Lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2005</study_first_submitted>
  <study_first_submitted_qc>April 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2005</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>February 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 2, 2015</results_first_posted>
  <last_update_submitted>February 26, 2015</last_update_submitted>
  <last_update_submitted_qc>February 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2015</last_update_posted>
  <responsible_party>
    <name_title>Anne MacDonald</name_title>
    <organization>Daiichi Sankyo</organization>
  </responsible_party>
  <keyword>Deep Vein Thrombosis,</keyword>
  <keyword>Anticoagulant,</keyword>
  <keyword>Venous thromboembolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edoxaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>15mg BID</title>
          <description>15mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="P2">
          <title>30mg QD</title>
          <description>30mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="P3">
          <title>30mg BID</title>
          <description>30mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="P4">
          <title>60mg QD</title>
          <description>60mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="P5">
          <title>60mg BID</title>
          <description>60mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="P6">
          <title>120mg QD</title>
          <description>120mg edoxaban administered once daily (QD)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="129"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="115"/>
                <participants group_id="P6" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="87"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>15mg BID</title>
          <description>15mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="B2">
          <title>30mg QD</title>
          <description>30mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="B3">
          <title>30mg BID</title>
          <description>30mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="B4">
          <title>60mg QD</title>
          <description>60mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="B5">
          <title>60mg BID</title>
          <description>60mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="B6">
          <title>120mg QD</title>
          <description>120mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="75"/>
            <count group_id="B3" value="129"/>
            <count group_id="B4" value="99"/>
            <count group_id="B5" value="115"/>
            <count group_id="B6" value="103"/>
            <count group_id="B7" value="606"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.6" spread="10.71"/>
                    <measurement group_id="B2" value="59.0" spread="11.06"/>
                    <measurement group_id="B3" value="60.1" spread="13.09"/>
                    <measurement group_id="B4" value="58.6" spread="11.90"/>
                    <measurement group_id="B5" value="58.8" spread="12.80"/>
                    <measurement group_id="B6" value="56.5" spread="12.83"/>
                    <measurement group_id="B7" value="58.5" spread="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="65"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="72"/>
                    <measurement group_id="B7" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="62"/>
                    <measurement group_id="B5" value="69"/>
                    <measurement group_id="B6" value="56"/>
                    <measurement group_id="B7" value="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="97"/>
                    <measurement group_id="B5" value="108"/>
                    <measurement group_id="B6" value="99"/>
                    <measurement group_id="B7" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="27"/>
                    <measurement group_id="B7" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="76"/>
                    <measurement group_id="B7" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevention of Venous Thromboembolism (VTE)</title>
        <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment (approximately 2 weeks post surgery).
Confirmed deep vein thrombosis ( both proximal and distal ) as assessed by unilateral or bilateral ascending contrast venograms 7 to 10 days following surgery Symptomatic and objectively proven Pulmonary Embolism (PE) prior to venography Symptomatic and objectively proven Deep Vein Thrombosis (DVT) prior to venography</description>
        <time_frame>2 weeks</time_frame>
        <population>modified ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>15mg BID</title>
            <description>15mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>30mg QD</title>
            <description>30mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>30mg BID</title>
            <description>30mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>60mg QD</title>
            <description>60mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>60mg BID</title>
            <description>60mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O6">
            <title>120mg QD</title>
            <description>120mg edoxaban administered once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Prevention of Venous Thromboembolism (VTE)</title>
          <description>The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment (approximately 2 weeks post surgery).
Confirmed deep vein thrombosis ( both proximal and distal ) as assessed by unilateral or bilateral ascending contrast venograms 7 to 10 days following surgery Symptomatic and objectively proven Pulmonary Embolism (PE) prior to venography Symptomatic and objectively proven Deep Vein Thrombosis (DVT) prior to venography</description>
          <population>modified ITT population</population>
          <units>percentage of patients with event</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="84"/>
                <count group_id="O6" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="11.7" upper_limit="28.7"/>
                    <measurement group_id="O2" value="13" lower_limit="12.3" upper_limit="29.9"/>
                    <measurement group_id="O3" value="10" lower_limit="5.7" upper_limit="16.9"/>
                    <measurement group_id="O4" value="13" lower_limit="10.9" upper_limit="26.8"/>
                    <measurement group_id="O5" value="16" lower_limit="12.3" upper_limit="27.5"/>
                    <measurement group_id="O6" value="17" lower_limit="14.0" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.238</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Prothrombin Time (PT) Results</title>
        <description>Intent to Treat (ITT) population</description>
        <time_frame>end of treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>15mg BID</title>
            <description>15mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>30mg QD</title>
            <description>30mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>30mg BID</title>
            <description>30mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>60mg QD</title>
            <description>60mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>60mg BID</title>
            <description>60mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O6">
            <title>120mg QD</title>
            <description>120mg edoxaban administered once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Prothrombin Time (PT) Results</title>
          <description>Intent to Treat (ITT) population</description>
          <population>ITT population</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.2" spread="2.3"/>
                    <measurement group_id="O2" value="-.1" spread="2.7"/>
                    <measurement group_id="O3" value=".7" spread="1.3"/>
                    <measurement group_id="O4" value=".8" spread="2.0"/>
                    <measurement group_id="O5" value="1.1" spread="1.9"/>
                    <measurement group_id="O6" value="1.8" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for International Normalized Ratio (INR) Results</title>
        <description>Intent to Treat (ITT) population</description>
        <time_frame>end of treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>15mg BID</title>
            <description>15mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>30mg QD</title>
            <description>30mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>30mg BID</title>
            <description>30mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>60mg QD</title>
            <description>60mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>60mg BID</title>
            <description>60mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O6">
            <title>120mg QD</title>
            <description>120mg edoxaban administered once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for International Normalized Ratio (INR) Results</title>
          <description>Intent to Treat (ITT) population</description>
          <population>ITT population</population>
          <units>INR ratio</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="95"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread=".2"/>
                    <measurement group_id="O2" value="0" spread=".3"/>
                    <measurement group_id="O3" value=".1" spread=".1"/>
                    <measurement group_id="O4" value=".1" spread=".2"/>
                    <measurement group_id="O5" value=".1" spread=".2"/>
                    <measurement group_id="O6" value=".2" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) Results</title>
        <description>Intent to Treat (ITT) population</description>
        <time_frame>end of treatment</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>15mg BID</title>
            <description>15mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O2">
            <title>30mg QD</title>
            <description>30mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O3">
            <title>30mg BID</title>
            <description>30mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O4">
            <title>60mg QD</title>
            <description>60mg edoxaban administered once daily (QD)</description>
          </group>
          <group group_id="O5">
            <title>60mg BID</title>
            <description>60mg edoxaban administered twice daily (BID)</description>
          </group>
          <group group_id="O6">
            <title>120mg QD</title>
            <description>120mg edoxaban administered once daily (QD)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for Activated Partial Thromboplastin Time (aPTT) Results</title>
          <description>Intent to Treat (ITT) population</description>
          <population>ITT population</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="87"/>
                <count group_id="O4" value="84"/>
                <count group_id="O5" value="94"/>
                <count group_id="O6" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.1" spread="22.0"/>
                    <measurement group_id="O2" value="-1.6" spread="25.3"/>
                    <measurement group_id="O3" value="2.5" spread="9.8"/>
                    <measurement group_id="O4" value="4.1" spread="17.0"/>
                    <measurement group_id="O5" value="5.8" spread="16.1"/>
                    <measurement group_id="O6" value="11.3" spread="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>15mg BID</title>
          <description>15mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="E2">
          <title>30mg QD</title>
          <description>30mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="E3">
          <title>30mg BID</title>
          <description>30mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="E4">
          <title>60mg QD</title>
          <description>60mg edoxaban administered once daily (QD)</description>
        </group>
        <group group_id="E5">
          <title>60mg BID</title>
          <description>60mg edoxaban administered twice daily (BID)</description>
        </group>
        <group group_id="E6">
          <title>120mg QD</title>
          <description>120mg edoxaban administered once daily (QD)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>lymphadentis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>obstructive inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>dislocation of joint prosthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>snake bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>contrast media reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>postprocedural fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>anemia postoperative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>hip arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphatase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>blood bilirubin abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>aspartate amniotransferase abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>hepatic enzyme increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>alanine aminotransferase increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphatase increase</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>sciatic nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>wound haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="56" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="66" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>anaemia post-operative</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="103"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="85"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="75"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="129"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="103"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A study site may not publish results of a study until after a coordinated multicenter publication has been submitted for publication or until one year after the study has ended, whichever occurs first. The study site will have the opportunity to publish results of the study, provided Daiichi Sankyo has had the opportunity to review and comment on the study site’s proposed publication prior to being submitted for publication with the advice of patent council and need for subject protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Victor Fernandez</name_or_title>
      <organization>Daiichi Sankyo, Inc.</organization>
      <phone>732-590-5000</phone>
      <email>vfernandez@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

